Precision BioSciences earnings calendar and gene-editing focus, shares remain a small-cap biotech play

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 21:18.

Precision BioSciences (US74019P1084) is a clinical-stage gene-editing company listed on Nasdaq in New York. The biotech is working toward its next quarterly earnings update while focusing resources on its Arcus platform and in vivo gene-editing pipeline, as outlined in its recent investor materials in the companys latest quarterly results release.

What recent filings show

In its first-quarter 2026 financial report, Precision BioSciences reported cash, cash equivalents and marketable securities that management believes are sufficient to fund operations into 2027, highlighting a cautious approach to spending while it advances lead programs. The accompanying SEC filing provides detailed cash runway information and R&D spending trends.

The companys update for the March 2026 quarter also summarized progress with its in vivo gene-editing candidates, including work in familial hypercholesterolemia and chronic hepatitis B, positioning Precision BioSciences alongside peers such as CRISPR Therapeutics and Intellia in the gene-editing field. A Reuters pipeline overview underlined the companys focus on these indications within the competitive landscape.

Analyst views on the small-cap biotech

On the analyst side, coverage remains limited given the companys small market capitalization, but available summaries point to a speculative profile with a mix of Hold and Buy ratings and a wide range of fair-value estimates tied closely to clinical milestones. Marketscreener consensus data aggregates these ratings and their associated price targets.

Broker commentary emphasizes that further clarity on partnership funding, trial timelines and regulatory feedback will be key for the stock, with comparisons frequently drawn to other Nasdaq-listed gene-editing developers working with big pharma partners. A recent analyst-style review on a US investing portal described the shares as a high-risk, high-reward biotech position.

The gene-editing platform behind the stock

Precision BioSciences generates its revenue potential from its proprietary Arcus genome-editing platform, which underpins in vivo gene-editing candidates in cardiovascular and infectious diseases. The company aims to monetize this platform through clinical success and collaborations with larger pharmaceutical partners in the US and abroad.

Where the stock trades today

Precision BioSciences shares trade on Nasdaq in US dollars; at the latest available close the stock changed hands at a low single-digit price level, reflecting its status as a small-cap clinical-stage biotech with binary pipeline risk.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.